Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The ChAdOx1 nCov-2019 coronavirus vaccine, developed by teams at the University of Oxford, has been shown to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years of age.

A scientist from the Jenner Institute processing blood samples © © Credit: University of Oxford, John Cairns

Severe necrotizing soft tissue infections (SENSEI) study: Protocol for a multi-centered audit.

Journal article

Yoshimura R. et al, (2026), JPRAS Open, 48, 331 - 336

Securing the future of immunisation: ESCMID’s vision

Journal article

Ramasamy MN. et al, (2026), CMI Communications, 3, 105167 - 105167

Enablers and barriers to participation in vaccine trials: a narrative synthesis.

Journal article

Daniel N. et al, (2026), Vaccine, 73

isk to child health: confusion and concern over changes to US vaccine policy.

Journal article

Pollard AJ. and Plotkin S., (2026), Lancet, 407, 553 - 556

Maternal views on RSV vaccination in the UK's second season.

Journal article

O'Hagan S. et al, (2026), Lancet Infect Dis

Load More